Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.40 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | GALR3 | O60755 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9837626 | 0.88 | ALDH1A1 (0.48) | ALDH1A1CHRM5CHRM1CHRM3PGR | |
| SCHEMBL292372 | 0.80 | ALDH1A1 (0.43) | ALDH1A1CHRM5CHRM1CHRM3PGR | |
| SCHEMBL1267156 | 0.77 | ALDH1A1 (0.40) | ALDH1A1CHRM5CHRM1CHRM3PGR | |
| SCHEMBL4229823 | 0.77 | ALDH1A1 (0.48) | ALDH1A1CHRM5CHRM1CHRM3PGR | |
| SCHEMBL71658 | 0.75 | ALDH1A1 (0.46) | ALDH1A1CHRM5CHRM1CHRM3PGR | |
| SCHEMBL2625 | 0.75 | ALDH1A1 (0.46) | ALDH1A1CHRM5CHRM1CHRM3PGR | |
| SCHEMBL4696007 | 0.73 | ALDH1A1 (0.44) | ALDH1A1CHRM5CHRM1CHRM3PGR | |
| SCHEMBL2517291 | 0.73 | ALDH1A1 (0.44) | ALDH1A1CHRM5CHRM1CHRM3PGR | |
| SCHEMBL1981927 | 0.73 | ALDH1A1 (0.44) | ALDH1A1CHRM5CHRM1CHRM3PGR | |
| SCHEMBL13034084 | 0.73 | ALDH1A1 (0.44) | ALDH1A1CHRM5CHRM1CHRM3PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006042200-A2 | METHOD FOR SYNTHESIS OF BETA-GLUCANS | EAST TENNESSEE STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2006-04-20 | — | — | WO | claimed |
| US-20060084630-A1 | Method for synthesis of beta glucans | ENSLEY HARRY E | 2006-04-20 | — | — | US | claimed |
| WO-2006042200-A3 | METHOD FOR SYNTHESIS OF BETA-GLUCANS | UNIV TENNESSEE EAST (US) | 2006-06-08 | — | — | WO | disclosed |
| WO-2006042200-A2 | METHOD FOR SYNTHESIS OF BETA-GLUCANS | EAST TENNESSEE STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006042200-A2 | METHOD FOR SYNTHESIS OF BETA-GLUCANS | EAST TENNESSEE STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2006-04-20 | — | — | WO | disclosed |
| US-20060084630-A1 | Method for synthesis of beta glucans | ENSLEY HARRY E | 2006-04-20 | — | — | US | disclosed |
| US-20060084630-A1 | Method for synthesis of beta glucans | ENSLEY HARRY E | 2006-04-20 | — | — | US | disclosed |
| EP-0287340-B1 | NOVEL ACYLATION PROCESS FOR THE SYNTHESIS OF HMG-COA REDUCTASE INHIBITORS | MERCK & CO. INC. (US) | 1993-09-29 | — | — | EP | disclosed |
| EP-0211416-B1 | NOVEL HMG-COA REDUCTASE INHIBITORS | MERCK & CO. INC. (US) | 1991-10-16 | — | — | EP | disclosed |
| US-4851436-A | ANTICHOLESTEROL AND ANTILIPEMIC AGENTS | MERCK & CO., INC. (US) | 1989-07-25 | — | — | US | disclosed |
| US-4845237-A | ANTIHYPERCHOLESTEROLEMIC COMPOUNDS | MERCK & CO., INC. (US) | 1989-07-04 | — | — | US | disclosed |
| EP-0287340-A2 | Novel acylation process for the synthesis of HMG-COA reductase inhibitors | MERCK & CO. INC. (US) | 1988-10-19 | — | — | EP | disclosed |
| US-4668699-A | 6-(NAPHTHYLETHYL)TETRAHYDROPYRAN-2-ONES; ANTILIPEMIC, ANTICHOLESTEROL | MERCK & CO., INC. (US) | 1987-05-26 | — | — | US | disclosed |
| US-4665091-A | 3-HYDROXY-3-METHYLGLUTARYL-COENZYME A, ANTICHOLESTEROL | MERCK & CO., INC. (US) | 1987-05-12 | — | — | US | disclosed |
| EP-0211416-A2 | Novel HMG-CoA reductase inhibitors | MERCK & CO. INC. (US) | 1987-02-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084630-A1 | Method for synthesis of beta glucans | DDOST, DAD1, STT3B | ALDH1A1 2580/4885CHRM5 2640/4885CHRM1 3331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.